Article info
PDFConcise reports
Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects
- Correspondence to:
Giovanni Lapadula
DIMIMP-Sezione di Reumatologia, Policlinico, Piazza G Cesare 11, 70124 Bari, Italy;g.lapadula{at}reumbari.uniba.it
Citation
Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects
Publication history
- Accepted June 29, 2006
- First published July 12, 2006.
Online issue publication
January 09, 2022
Article Versions
- Previous version (9 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2007 by Annals of the Rheumatic Diseases